Skip to content

Janux Therapeutics

US · JANX #3187 by market cap Listed 2021
10.08 -0.21 -2.04%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 10.14 -1.46%
After-hours 10.15 +0.69%
20.2410.0810.082026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on JANX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -53.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 8.7% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Operating margin -1,576.7% Better than 2%
Net margin -1,136.3% Better than 2%
Return on equity -11.5% Better than 19%
Return on invested capital -15.6% Better than 15%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -42.0% Better than 9%
6-month return -30.6% Better than 18%
12-month return (ex latest month) -42.2% Better than 5%
Distance below 52-week high 71.5% Better than 5%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 39.0x Better than 99%
Debt to assets 2.2% Better than 87%
Interest coverage -31.9x Better than 9%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 75.0% Better than 51%
Upside to average target 205.6% Better than 95%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.35%
1M -41.40%
3M -41.67%
6M -30.00%
YTD -26.96%
1Y -64.74%
3Y +11.38%
5Y -43.62%

Key statistics

Price & volume

Prev close
10.29
Open
10.11
Day range
10.05 - 10.54
Avg price
10.21
Volume
1.11M
Turnover
11.38M
Amplitude
4.76%
52-week range
10.05 - 35.34

Valuation

P/E
-5.51
P/E (TTM)
-6.34
P/B
0.68
EPS
-1.83
Net profit
-111.97M
Net assets
911.63M

Share structure

Market cap
616.73M
Float cap
459.17M
Shares out
61.18M
Float shares
45.55M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-06-11
52-week range 0% of range
10.05 35.34

71.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-1.40M net over the window

Short interest

Shares short
5.33M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Janux Therapeutics (JANX)?

Janux Therapeutics last traded at 10.08. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Janux Therapeutics's market cap?

About 616.73M.

What is the P/E ratio of Janux Therapeutics?

The trailing twelve-month P/E is -6.34. The Valuation tab shows it against the stock's own five-year range.

Does Janux Therapeutics pay a dividend?

Janux Therapeutics does not currently pay a regular dividend.

Is Janux Therapeutics a buy according to analysts?

The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 30.80, which implies 205.6% upside from the current price. This is not investment advice.

What is Janux Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Janux Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 20:02:21 · For reference only, not investment advice and not tailored to your situation.

Janux Therapeutics discussion 0 comments

Add a comment